Li Guoyu, Wang Yanghao, Wang Weizhou, Lv Guodong, Li Xiang, Wang Jingying, Liu Xiuyu, Yuan Daolang, Deng Shoujun, You Dingyun
Department of Colorectal Surgery, Yunnan Cancer Hospital, Kunming, Yunnan, China.
Department of Pathology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Front Genet. 2024 Dec 5;15:1509342. doi: 10.3389/fgene.2024.1509342. eCollection 2024.
BIRC5 (Survivin) is a crucial anti-apoptotic protein overexpressed in various cancers, promoting tumor growth and treatment resistance. This study investigates its expression across 33 cancer types and explores its diagnostic, prognostic, and immune-related significance.
We analyzed RNA-seq data from TCGA and protein expression data from the Human Protein Atlas. Expression levels were compared between tumor and normal tissues. Correlations with molecular and immune subtypes were explored using TISIDB. Prognostic significance was evaluated through survival analysis, Cox regression, and ROC curve analysis. The PPI network was constructed using STRING.
BIRC5 was significantly overexpressed in tumor tissues across 33 cancer types, with higher expression levels observed in tumors compared to normal tissues. The protein expression analysis revealed a similar trend. BIRC5 expression was significantly correlated with various molecular and immune subtypes in multiple cancer types. Survival analysis indicated that high BIRC5 expression was associated with poor prognosis across multiple cancers, including lung adenocarcinoma (LUAD) and kidney renal clear cell carcinoma (KIRC). ROC analysis showed that BIRC5 exhibited strong diagnostic potential, with high AUC values (>0.9) in several cancers. The PPI network analysis identified key interacting proteins involved in the cell cycle and tumor progression, further supporting BIRC5's role in cancer biology. Functional experiments in lung adenocarcinoma (LUAD) revealed that BIRC5 upregulation enhances cell proliferation, migration, and invasion, while its knockdown suppresses these activities.
BIRC5 is a promising diagnostic and prognostic biomarker in multiple cancers. Its association with immune subtypes suggests a potential role in the tumor immune microenvironment. These findings support BIRC5 as a therapeutic target for cancer treatment.
BIRC5（存活素）是一种关键的抗凋亡蛋白，在多种癌症中过度表达，促进肿瘤生长和治疗抵抗。本研究调查了其在33种癌症类型中的表达情况，并探讨了其诊断、预后及免疫相关意义。
我们分析了来自癌症基因组图谱（TCGA）的RNA测序数据以及来自人类蛋白质图谱的蛋白质表达数据。比较了肿瘤组织与正常组织之间的表达水平。使用TISIDB探索了与分子和免疫亚型的相关性。通过生存分析、Cox回归和受试者工作特征（ROC）曲线分析评估了预后意义。使用STRING构建了蛋白质-蛋白质相互作用（PPI）网络。
BIRC5在33种癌症类型的肿瘤组织中均显著过度表达，与正常组织相比，肿瘤中的表达水平更高。蛋白质表达分析显示了类似的趋势。BIRC5的表达与多种癌症类型中的各种分子和免疫亚型显著相关。生存分析表明，BIRC5高表达与多种癌症的不良预后相关，包括肺腺癌（LUAD）和肾透明细胞癌（KIRC）。ROC分析表明，BIRC5具有很强的诊断潜力，在几种癌症中的曲线下面积（AUC）值较高（>0.9）。PPI网络分析确定了参与细胞周期和肿瘤进展的关键相互作用蛋白，进一步支持了BIRC5在癌症生物学中的作用。肺腺癌（LUAD）的功能实验表明，BIRC5上调增强细胞增殖迁移和侵袭，而其敲低则抑制这些活性。
BIRC5是多种癌症中有前景的诊断和预后生物标志物。其与免疫亚型的关联表明其在肿瘤免疫微环境中具有潜在作用。这些发现支持将BIRC5作为癌症治疗的靶点。
